Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is a single-arm,exploratory clinical study, to evaluate the effectiveness and
safety of apatinib mesylate combined with albumin-bound paclitaxel for second-line treatment
of advanced triple negative breast cancer.